0
Marker Therapeutics, Inc. Banner Image

Marker Therapeutics, Inc.

  • Ticker MRKR
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Marker Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Houston, Texas
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumorMore targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, they believe that their product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Marker Therapeutics, Inc.

Most Recent Annual Report

Marker Therapeutics, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports